drugset / Trial / NCT06768905
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Phase 1/2
Recruiting
30 enrolled
University of Texas Southwestern Medical Center
Actinium Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.
Timeline
- Start
- 2025-04-25
- Primary completion
- 2029-05
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IODINE I 131 APAMISTAMAB | Monoclonal antibody | 1850 mbq | — |
| Background | CAR-T cell | Cell therapy | — | — |